Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Small Cell Lung Carcinoma 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Lung Neoplasms 4Head and Neck Neoplasms 4Biliary Tract Neoplasms 4Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma 2Liver Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Bile Duct Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Breast Neoplasms 1Resectable Biliary Tract Cancer 1Radiation Pneumonitis 1

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Resectable Biliary Tract Cancer × durvalumab × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡